Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lung Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 7Lymphoma, Large B-Cell, Diffuse 5Leukemia 5Ovarian Neoplasms 4Lymphoma 4Squamous Cell Carcinoma of Head and Neck 3Precancerous Conditions 3Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, Large-Cell, Anaplastic 3Immunoblastic Lymphadenopathy 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Central Nervous System Neoplasms 3Burkitt Lymphoma 3Adenocarcinoma Of Esophagus 3Tongue Neoplasms 2Testicular Germ Cell Tumor 2Stomach Neoplasms 2Sarcoma 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasm Metastasis 2Myeloproliferative Disorders 2

Interventions

Dexamethasone 38Melphalan 20Bortezomib 18Cyclophosphamide 17Calcium Dobesilate 14Filgrastim 13daratumumab 11Peripheral Blood Stem Cell Transplantation 10pomalidomide 9Lenalidomide 8fludarabine phosphate 7dexamethasone acetate 6Whole-Body Irradiation 6Mycophenolic Acid 6Granulocyte Colony-Stimulating Factor 5Cyclosporine 5venetoclax 4ixazomib 4dexamethasone 21-phosphate 4Thalidomide 4Etoposide 4Busulfan 4auricularum 3Tacrolimus 3Radiotherapy 3Focal Adhesion Protein-Tyrosine Kinases 3Epoetin Alfa 3Doxycycline 3Darbepoetin alfa 3Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Immunoglobulin Light-chain Amyloidosis × Microarray Analysis × Clear all
NCT00520767 2023-12-22

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
35 enrolled 7 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡